PROPANC BIOPHARMA, INC. (OTCMKTS:PPCHD) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03 Amendments to Articles of Incorporation or Bylaws;
Change in Fiscal Year
On April 19, 2017, Propanc Health Group Corporation (the Company)
filed with the Division of Corporations, Delaware Department of
State two certificates of amendment to its certificate of
incorporation.
The first amendment provided for a reverse stock split of the
Companys common stock, par value, $0.001 per share (the Common
Stock), at a ratio of 1-for-250 (the Reverse Split). This
amendment further provided for a reduction in the number of
authorized shares of Common Stock to 100 million, as well as for
a reduction in the number of authorized shares of preferred stock
to 1,500,005 (the Authorized Share Reduction). The Companys
intention to effect both the Reverse Split and the Authorized
Share Reduction were previously disclosed in a definitive
information statement on Schedule 14C filed on March 13, 2017 and
in a current report on Form 8-K filed on March 31, 2017.
The second amendment provided that the Companys name would change
to Propanc Biopharma, Inc. (the Name Change). The intent to
effect the Name Change had previously been disclosed by the
Company in a current report on Form 8-K on March 31, 2017.
Both amendments had an effective date and time of 12:01 a.m. on
April 20, 2017.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
3.1.1 Certificate of Amendment to the Companys Certificate of
Incorporation relating to the Reverse Split and the Authorized
Share Reduction
3.1.2 Certificate of Amendment to the Companys Certificate of
Incorporation relating to the Name Change
About PROPANC BIOPHARMA, INC. (OTCMKTS:PPCHD)
Propanc Biopharma, Inc., formerly Propanc Health Group Corporation, is an early-stage healthcare company that is focused on developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancer. The Company has developed a composite formulation of anti-cancer compounds, which together exert a range of effects designed to control or prevent tumors from recurring and spreading through the body. The Company’s solution is to develop and commercialize a long-term therapy to prevent tumor recurrence and metastases. It is developing pro-enzyme therapy for the treatment and prevention of the development of carcinomas from solid tumors. The Company’s products include PRP and PRP-DCM. The Company’s PRP is a formulation consisting of two pro-enzymes: trypsinogen and chymotrypsinogen, plus the enzyme amylase (1, 4-alpha-D-glucan glucanohydrolase). The pro-enzymes in PRP, typsinogen and chymotrypsinogen, exhibit specificity for tumor cells and not normal cells. PROPANC BIOPHARMA, INC. (OTCMKTS:PPCHD) Recent Trading Information
PROPANC BIOPHARMA, INC. (OTCMKTS:PPCHD) closed its last trading session down -0.06 at 1.52 with 36,486 shares trading hands.